TORONTO, March 26, 2019 (GLOBE NEWSWIRE) -- Aura Health Inc. (the “Company” or “Aura”) (CSE:BUZZ) is pleased to announce the appointment of Alain Dobkin to its board of directors, subject to regulatory approval. Alain is a private equity investor with more than 20 years of investment and advisory experience, including 13 years with Citigroup Investment Bank in New York and Tel Aviv. Additionally, he was the Director of Citigroup’s Israel Investment Bank, where he served as advisor on strategic mergers and acquisitions and equity and debt capital raising transactions from both public and private markets globally. Alain brings a wealth of experience in global and Israeli finance and M&A having managed transactions with aggregate value of ~US$40 billion.



To make room for Mr. Dobkin, Chris Carl has volunteered to step down as President and from Aura’s board to focus on his role as CEO of DigiCrypts.

Daniel Cohen, Aura’s CEO, commented, “Alain brings significant pedigree to Aura’s board of directors both from a financial perspective and a knowledge of Israeli and European markets. As we continue to build out our asset base in Israel and Europe, Alain being situated in Tel Aviv will be a tremendous asset to our business. We wish the best of luck to Chris in his new endeavor.”

About Aura Health Inc.

Aura Health is building an international network of vertically integrated cannabis assets. Through a product line of cannabis-infused edible products and oil extracts, Aura is dedicated to building a high margin downstream business in the medical marijuana sector. The Company holds debt convertible into 54% equity of HolyCanna, a cultivation and nursery license holder in Israel. Aura has also entered into a definitive agreement to acquire 80% of Pharmadrug, a German medical cannabis and pharmaceutical distributor, as well as a binding letter of intent to purchase 57% of CannabiSendak, the builder of a network of high-profile dispensaries in Israel. The Company also owns a 30% interest in four medical marijuana clinics in the U.S. Sun Belt.

For further information, please contact:

Daniel Cohen, CEO

Aura Health Inc.

(647) 202-1824

David Posner, Chairman

Aura Health Inc.

(647) 985-6727

Caution Regarding Forward-Looking Information:

THE CANADIAN SECURITIES EXCHANGE HAS NOT REVIEWED NOR DOES IT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

This news release may contain “forward-looking information” within the meaning of applicable Canadian securities laws. Generally, forward-looking information can be identified by the use of words and phrases such as “plans”, “expects”, “continues”, “intends”, “anticipates”, or “believes”, or variations of such words and phrases indicating that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken or occur. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Such statements include those relating to regulatory approval of a new director and the Company’s future expansion plans in Israel and Europe. There is no certainty that any of these events will occur. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct.

Additionally, there are known and unknown risk factors which could cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. These risks and uncertainties include, without limitation, regulatory approval, rapidly developing global regulatory regimes relating to cannabis, and/or inability to successfully execute intended strategies and business objectives. All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information, except as required by applicable securities laws.

The Company's securities have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons", as such term is defined in Regulation S under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful.